" /> Cilgavimab - CISMeF





Preferred Label : Cilgavimab;

NCIt definition : A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : 1KUR4BN70F;

CAS number : 2420563-99-9;

Molecule name : AZD 1061; COV2-2130; AZD-1061;

NCI Metathesaurus CUI : CL1642840;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
10/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.